The role of sacubitril/valsartan in patients with advanced chronic kidney disease and heart failure

7th International Congress of Cardionephrology KARNEF (2025) [pp. 131-136]

AUTHOR(S) / АУТОР(И): Robert Ekart , Nejc Piko, Luka Varda, Tadej Petreski, Sebastjan Bevc, Radovan Hojs

Download Full Pdf   

DOI: 10.46793/KARNEF25.136E

ABSTRACT / САЖЕТАК:

Chronic kidney disease and heart failure (HF) are closely related conditions that often coexist and complicate each other. Both conditions can exacerbate disease progression and influence treatment strategies.

Angiotensin receptor- neprilysin inhibitors (ARNIs) are playing an increasingly important role in the treatment of HF. ARNIs combine two mechanisms of action: sacubitril is a neprilysin inhibitor that enhances natriuretic peptides, resulting in vasodilation, diuresis and reduced cardiac workload; valsartan is an angiotensin II receptor blocker that reduces the effects of the renin-angiotensin-aldosterone system, lowers blood pressure and reduces fluid retention.

The PARADIGM-HF study (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan significantly reduces mortality and hospitalisation rates in patients with HF and reduced ejection fraction. In patients with advanced kidney disease, who have the highest prevalence of HF, the efficacy and safety of sacubitril/valsartan remains uncertain. However, evidence on the benefit of ARNI in HF patients with end-stage renal disease undergoing dialysis is limited.

KEYWORDS / КЉУЧНЕ РЕЧИ:

REFERENCES / ЛИТЕРАТУРА:

  • Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, Leon MB, et al. Diagnosis and management of cardiovascular disease in advanced and end-stage renal disease. J Am Heart Assoc 2016; 5:e003648. https://doi.org/10.1161/jaha.116.003648
  • House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;95:1304–17. https://doi.org/10.1016/j.kint.2019.02.022
  • Nguyen DV, Le TN, Truong BQ, Nguyen HTT. Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis. Eur J Heart Fail. 2024 Sep 9. doi: 10.1002/ejhf.3454
  • Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, Leon MB, et al. Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. J Am Heart Assoc. 2016;5(8):e003648. doi: 10.1161/JAHA.116.003648.
  • McMurray JVV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med.2014;371(11):993-1004. doi: 10.1056/NEJMoa1409077.
  • Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032
  • Khan MS, Ahmed A, Greene SJ, Fiuzat M, Kittleson MM, Butler J, et al. Managing heart failure in patients on dialysis: State-of-the-art review. J Card Fail 2023;29:87–107. https://doi.org/10.1016/j.cardfail.2022.09.013
  • Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C. Chronickidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant 2020;35:558–64. https://doi.org/10.1093/ndt/gfz058
  • Cho IJ, Kang SM. Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Res Clin Pract 2021;40:555–65. https://doi.org/10.23876/j.krcp.21.900
  • Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, et al. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. J Card Fail. 2018; 24:266-75.
  • Ushijima K, Ando H, Arakawa Y, Aizawa K, Suzuki C, Shimada K, et al. Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor. Pharmacol Res Perspect. 2017;5 (4): e00336. DOI:1002/prp2.336
  • Uijl E, t Hart DC, Roksnoer LCW, Clahsen-van Groningen MC, van Veghel R, Garrelds IM, et al. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. J Hypertens.2020;38:755-64. DOI:1097/HJH.0000000000002326
  • Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharma-cokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-14. DOI:1177/0091270009343932
  • Feng Z, Wang X, Zhang L, Apaer R, Xu L, Ma J, et al. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Blood Purif. 2022;51:270-279. DOI:1159/000519643
  • He Y, Jin Y, Xue H, Liu R, Zhang M, Liao R, et al. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients. Nephrol Dial Transplant. 2023;38:1880-9. doi: 10.1093/ndt/gfad038.
  • Zhou W, Yang X, Jin JJ, Cheng M, Li Y, Bai Y, et al. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2024;56:181-190. doi: 10.1007/s11255-023-03599-w.
  • Yang X, Jin J, Cheng M, Xu J, Bai Y. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis. Ren Fail.2024;46:2349135. doi: 10.1080/0886022X.2024.2349135.
  • Chang HY, Lin CC, Chao CJ, Lin YC, Wang YC, Liao CT, et al. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease. Mayo Clin Proc. 2023;98:88-99. doi: 10.1016/j.mayocp. 2022.06.007.
  • Lee WC, Liao TW, Chen TY, Fang HY, Fang YN, Chen HC, et al. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. Cardiovasc Drugs Ther. 2024;38:505-15. doi: 10.1007/s10557-022-07421-0.
  • Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018;138:1505-14. doi: 10.1161/CIRCULATIONAHA.118.034818.
  • Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. Eur J Pharmacol. 2020;884:173444. doi: 10.1016/j.ejphar.2020.173444.
  • Gan L, Lyu X, Yang X, Zhao Z, Tang Y, Chen Y, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med (Lausanne) 2022;9:877237. https://doi.org/10.3389/fmed.2022.877237